Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor

Blood (2018) 132 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2018-99-118264

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Narjis Rizwan, BSMedTech, MPhil, PhD, Yandong Shen, BMedSc (Hon), Edwin Iwanowicz, PhD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Kyle R Crassini, MBBS, BSc, Richard Christopherson, PhD Emeritus Professor, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 3145.

https://doi.org/10.1182/blood-2018-99-115555

Published: 2018

Journal Articles

DNA Damage in Haemopoeitic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation

Lijun Bai, PhD MBBS, Oliver Giles Best, PhDBSc, Wei Xia, PhD MBBS, Lyndsay Peters, Kelly Wong, Christopher Ward, PhD MBBChir, Matthew Greenwood, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2018-99-115530

Published: 2018

Journal Articles

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Kyle R Crassini, MBBS,BE,BSc, Yandong Shen, BMedSc (Hon), Richard Christopherson, PhDEmeritus Professor, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 4279.

https://doi.org/10.1182/blood.V130.Suppl_1.4279.4279

Published: 2017

Journal Articles

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS,BE,BSc, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Richard Christopherson, PhDEmeritus Professor, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 5340.

https://doi.org/10.1182/blood.V130.Suppl_1.5340.5340

Published: 2017

Journal Articles

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Kyle R Crassini, MBBS,BE,BSc, Eva Zhang, MBBS, Shalini Balendran, MBBS, Jane Freeman, BA,FRACP,FRCPA,MBBS,MPhil,MSc, Oliver Giles Best, PhDBSc, Cecily Forsyth, FRACP, FRCPA, MBBS, Naomi Mackinlay, Ping Han, MDPhD, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2017) 130 (Supplement 1): 5321.

https://doi.org/10.1182/blood.V130.Suppl_1.5321.5321

Published: 2017

Journal Articles

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

Oliver Giles Best, PhDBSc, Kyle Crassini, MBBS BSc, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA

Blood (2014) 124 (21): 4693.

https://doi.org/10.1182/blood.V124.21.4693.4693

Published: 2014

Journal Articles

The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment

Oliver Giles Best, PhDBSc, Tahni Pyke, BSc (Hons), Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA

Blood (2014) 124 (21): 3326.

https://doi.org/10.1182/blood.V124.21.3326.3326

Published: 2014

Journal Articles

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Oliver Giles Best, PhDBSc

Blood (2014) 124 (21): 3330.

https://doi.org/10.1182/blood.V124.21.3330.3330

Published: 2014

Journal Articles

Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.

Anton Parker, Shilu Amin, Tricia Zwiefelhofer, Ben Gregory, Helen White, PhD, Oliver Giles Best, PhD, Nick Cross, PhD, Jelena Mann, PhD, Mathias Ehrich, MD, David Graham Oscier, MD

Blood (2008) 112 (11): 2246.

https://doi.org/10.1182/blood.V112.11.2246.2246

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

DNA Damage in Haemopoeitic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only